Literature DB >> 9088366

Re-operations of supratentorial anaplastic astrocytomas.

L Sipos1, D Afra.   

Abstract

Results of re-operations of 99 adult patients with recurrent supratentorial lobar glioblastomas (60 patients) and anaplastic astrocytomas (39 patients) have been reviewed. In all cases both surgical interventions were performed at the same institute. Age of patients with glioblastoma varied between 19 and 64 and with anaplastic astrocytoma between 21 and 68 years, with a mean value of 48 and 36 years, respectively. The median interval between the first and second operations was 47 weeks for patients with glioblastoma and 83 weeks with anaplastic astrocytoma. The mortality rate of the re-operations was 3%. Following re-operation radio- and/or chemotherapy was applied in most of the cases. Median survival time after re-operation was 18.5 weeks in patients with glioblastoma and 55 weeks with anaplastic astrocytoma. Survival curves were calculated according to Kaplan-Meier method and for statistical evaluation the generalized Wilcoxon test and multiple linear regression method were used. Histologically lower grade tumour at the first operation and longer interval between the two operations proved to influence positively and dedifferentiation of the primary tumour negatively the survival time.

Entities:  

Mesh:

Year:  1997        PMID: 9088366     DOI: 10.1007/bf02747187

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

Review 2.  The role of cytoreductive surgery in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Steven N Kalkanis; John M Buatti; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-23       Impact factor: 4.130

3.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

4.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

5.  Apoptosis and p53 expression in human gliomas.

Authors:  L Sipos; Z Szegedi; I Fedorcsák; D Afra; B Szende
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

6.  Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III.

Authors:  B Suchorska; C Hamisch; H Treuer; K Mahnkopf; R E Lehrke; M Kocher; M I Ruge; J Voges
Journal:  J Neurooncol       Date:  2016-07-15       Impact factor: 4.130

7.  Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma.

Authors:  Andrew L Ko; Kathleen R Fink; Keith M Stelzer; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.